Commitment to Quality and Reliability Drives Septa’s Efforts to Address Medication Shortages in Canada

Mississauga, ON — April 27, 2024 — Septa Pharma Inc., a leading provider of essential medications in Canada, continues to demonstrate its unwavering commitment to ensuring uninterrupted access to vital drugs with its recent approval from Health Canada to import Aminophylline inj. This approval comes as a strategic response to mitigate a critical shortage of Aminophylline, a medication used to treat respiratory conditions, within Canada.

In a landscape where access to essential medications can be unpredictable, Septa stands as a beacon of reliability and support for healthcare providers and patients alike. With a steadfast dedication to quality and safety, Septa navigates the complexities of the pharmaceutical supply chain to maintain a consistent availability of life saving medications, even during times of scarcity.

Drawing upon years of expertise and a robust network of over 200+ pharmaceutical manufacturers and sourcing partners worldwide, Septa strives to bridge the gap between demand and availability, empowering healthcare professionals to deliver optimal care to those in need. This commitment is further underscored by Septa’s understanding of the urgency of the situation and its dedication to providing timely solutions to alleviate the impact of drug shortages on Canadian communities.

The approval from Health Canada to import Aminophylline inj. exemplifies Septa’s proactive approach to addressing medication shortages. By leveraging its global network and adhering to stringent quality standards, Septa ensures that Canadian healthcare providers have access to the medications necessary to effectively treat patients.

“We recognize the importance of Aminophylline in managing respiratory conditions, and we are committed to ensuring its availability to healthcare providers across Canada,” states the CEO. “This approval reflects our ongoing efforts to prioritize the well-being of patients and support the healthcare system during challenging times.”

As Septa continues to navigate the evolving landscape of global pharmaceutical supply chain, its dedication to quality, reliability, and timely solutions remains unwavering. Through initiatives such as the importation of Aminophylline, Septa reaffirms its position as a trusted partner in healthcare, providing essential medications with integrity and compassion.

About Septa: Septa is a global healthcare and pharmaceutical conglomerate, offering health advancing products and niche services to advance and nourish the quality of life domestically and globally. For more information about Septa and its commitment to ensuring uninterrupted access to essential medications, visit www.SeptaLife.com.


For media inquiries, please contact:

Public Relations
Septa Pharma Inc.
Email: pr@septapharma.com
Phone: +1 (905) 564-5665

Septa Pharma Inc. to Participate in World Orphan Drug Congress 2024

Boston, MA — April 24, 2024 — Septa Pharma Inc., a global pharmaceutical company dedicated to addressing unmet medical needs in rare diseases, is excited to announce its attendance at the highly anticipated World Orphan Drug Congress 2024 in Boston. This premier event, renowned for its focus on orphan drugs and rare diseases, provides a valuable platform for industry collaboration, innovation, and partnership.

As an esteemed attendee, Septa looks forward to engaging with fellow participants, industry experts, and stakeholders to exchange insights, foster collaborations, and advance efforts in rare disease therapeutics. The World Orphan Drug Congress serves as a critical forum for driving progress in the development of treatments for rare and underserved conditions, aligning closely with Septa’s mission to improve patient outcomes and quality of life.

Septa recognizes the importance of forging meaningful connections and exploring potential business opportunities at events like the World Orphan Drug Congress. As such, the company welcomes inquiries from fellow attendees interested in discussing collaboration prospects, partnership opportunities, or any other mutually beneficial initiatives.

For those wishing to schedule a meeting with Septa representatives to explore potential business opportunities, please reach out via email to info@septapharma.com. Team Septa looks forward to connecting with industry peers, sharing insights, and exploring avenues for collaboration that can further advance the field of rare disease therapeutics.

“We are excited to participate in the World Orphan Drug Congress 2024 and engage with fellow stakeholders in the rare disease community,” said Team Septa. “This event provides an excellent opportunity to exchange ideas, forge partnerships, and collectively drive progress towards addressing unmet medical needs in rare diseases.”

Septa encourages all attendees of the World Orphan Drug Congress 2024 to connect with its representatives and learn more about the company’s mission, initiatives, and commitment to advancing rare disease therapeutics.

For more information about Septa and its participation in the World Orphan Drug Congress 2024, please visit www.SeptaLife.com.

For media inquiries, please contact:

Public Relations
Septa Pharma Inc.
Email: pr@septapharma.com
Phone: +1 (905) 564-5665